This may be related to the renal protective effects of hypoglycaemic agents45–47, such as SGLT-2 inhibitors, which not only promote anti-inflammatory and antifibrotic pathways, improve renal oxygenation, and reduce glomerular hypertension and hyperfiltration but also reduce the renal hypoxia characteristic of diabetes, thus exerting effects similar to those of β-blockers in the heart. The gene discussed is SLC5A2; the disease is diabetes mellitus.